ALNY · Alnylam Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $31.02B |
| P/E | 38.39 |
| Float | 133.4M |
| Beta | 0.37 |
| Volatility | 9.3% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 61.9 |
| Price | 235.27 |
| Change | +1.48% |
| Prev Close | 231.83 |
| Open | 235.18 |
| Day Low | 231.29 |
| Day High | 237.98 |
| Avg Vol | 1 |
| Avg $ Vol | $283.7M |
| 52W High | 495.55 |
| 52W Low | 197.81 |
| 52W Pos | 12.6% |
| From High | −52.52% |
| From Low | +18.94% |
| Max DD 1Y | −58.17% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.35% |
| SMA 50 | −1.32% |
| SMA 200 | −20.06% |
| RSI (14) | 46.9 |
| Vol 30D | 41.5% |
| Vol 90D | 70.5% |
| 1Y Range | 198–496 |
| Daily bars | 900 |
| Perf Week | −0.37% |
| Perf Month | −5.57% |
| Perf Quarter | −14.98% |
| Perf Half Y | −25.13% |
| Perf Year | −50.70% |
| Perf YTD | −41.21% |
| Prev Day | +1.48% |
| Clavix | C+ |
| Debt / Eq | 0.86 |
| Curr Ratio | 2.76 |
| Int Cover | 4.6× |
| FCF Margin | 12.5% |
| Rev Growth | +65.2% |
| Profit | Profitable |
| Leverage | Very High |
| Sector rank | 26 / 35 |
Clavix risk grade
regraded every trading dayALNY grades C+, 61.9 of 100. Steadiest on Macro Resilience (65), most exposed on Price Stability (41, fragile). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 26 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ALNY | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.37 | 0.51 |
| Volatilityannualized | 9.3% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −58.2% | — |
| Typical daily movemedian absolute daily change | 1.58% | — |
| Days beyond ±3%of the last 252 sessions | 53 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ALNY | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.37 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ALNY | |
|---|---|
| 1 week | −0.4% |
| 1 month | −5.6% |
| Year to date | −41.2% |
| 1 year | −50.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ALNY | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 16 Aug |
| Average score0 most bearish, 100 most bullish | 57 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 8 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 8 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ALNY | |
|---|---|
| Revenue growthyear over year | +65.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openTwenty-six analysts who cover Alnylam Pharmaceuticals have given the stock an average rating of 'Moderate Buy,' according to MarketBeat Ratings. Six analysts rate it a hold and seventeen rate it a buy.
UBS Group began covering Alnylam Pharmaceuticals stock on Thursday, assigning it a 'buy' rating and a $354 price target. The article provides no other details about the company's business.
A bullish investment thesis on Alnylam Pharmaceuticals was published on September 11th at a price of $248.68, but the stock has since dropped 8.70%. The decline reflects ongoing concerns about slower-than-expected demand for AMVUTTRA following a recent guidance cut, with the article comparing ALNY to peers IONS and ARWR on pipeline growth potential.
Alnylam lowered its revenue forecast, which unsettled investors, though analysts still broadly expect the biotech's drug sales to grow.
Alnylam lowered its revenue forecast for the full year, saying sales of its drug Amvuttra grew more slowly than it expected. The article compares this to Ionis, which had two drug-development setbacks in July, and argues one is the better buy.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
| RVMD | Revolution Medicines Inc | B- | $38.14B | — | 1.44 | Compare |
| INCY | Incyte Corp | B+ | $22.92B | 14.21 | 0.79 | Compare |
| UTHR | United Therapeutics Corp | B | $22.87B | 17.44 | 0.50 | Compare |
| INSM | Insmed Inc | C | $21.02B | — | 0.83 | Compare |
| NTRA | Natera Inc | B- | $56.71B | — | 1.54 | Compare |
| EXEL | Exelixis Inc | B+ | $15.42B | 17.92 | 0.44 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $14.05B | 16.85 | 0.39 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.